ANSWER: C

Rationale:

Ketamine's open-channel blockade of the NMDA receptor is use-dependent: the drug can only enter the channel pore when the channel is open, and therefore the frequency of channel opening directly determines the degree of blockade achieved at any given ketamine concentration. GABAergic interneurons in the prefrontal cortex fire tonically — that is, they fire at continuous, relatively high rates under baseline conditions — which means their NMDA receptor channels open frequently. This high opening frequency gives ketamine substantially more opportunities to enter and occupy the channel pore compared with pyramidal neurons, which fire phasically and at lower baseline rates. The result is preferential NMDA receptor blockade on GABAergic interneurons, suppression of their inhibitory output, disinhibition of pyramidal neurons, and the glutamate burst that initiates the downstream antidepressant cascade. This use-dependent selectivity is not absolute but is sufficient at subanesthetic concentrations to shift the balance toward net disinhibition of pyramidal output.

• Option A: Option A is incorrect because the preferential blockade of GABAergic interneurons is explained by their firing rate (use-dependence), not by a distinct subunit composition conferring higher ketamine affinity. While NMDA receptors do contain different subunit combinations across cell types, the pharmacologically relevant explanation for this selectivity at antidepressant doses is the use-dependent mechanism driven by tonic firing.
• Option B: Option B is incorrect because ketamine does not rely on a selective membrane transporter for neuronal entry. It is a lipophilic molecule that crosses cell membranes by passive diffusion. There is no GABAergic interneuron-specific intracellular accumulation mechanism.
• Option D: Option D is incorrect because the preferential effect is not explained by receptor density per unit membrane area. Use-dependence — the requirement for channel opening before blockade can occur — is the mechanistic basis for selective interneuron blockade, not a quantitative difference in receptor number.
• Option E: Option E is incorrect because GABAergic interneurons do not have lower resting membrane potentials that constitutively relieve Mg2+ block. The voltage-dependent Mg2+ block of the NMDA channel requires sufficient membrane depolarization during active firing, not a chronically hyperpolarized state. The relevant variable is firing rate (channel opening frequency), not resting potential.

ANSWER: B

Rationale:

The AMPA receptor is the critical downstream target activated by the ketamine-induced glutamate burst. AMPA receptors are ionotropic glutamate receptors that open in response to glutamate binding alone, without requiring membrane depolarization or removal of a Mg2+ channel block, and without requiring a co-agonist at a separate binding site. This distinguishes AMPA receptors from NMDA receptors, which require simultaneous glutamate binding, glycine or D-serine co-agonist binding, and membrane depolarization for full activation. Because AMPA receptors lack the voltage-dependent Mg2+ block that limits NMDA receptor activation at resting membrane potentials, they can respond to the glutamate burst even while NMDA receptors remain blocked by ketamine. AMPA receptor activation during the glutamate burst initiates intracellular signaling cascades that stimulate BDNF release from dendritic compartments, activating TrkB receptors and setting in motion the mTORC1-dependent synaptogenesis that constitutes the structural basis of the antidepressant effect.

• Option A: Option A is incorrect because the metabotropic glutamate receptor 2 is not the receptor driving the antidepressant signaling cascade after ketamine administration. mGluR2 is a presynaptic autoreceptor that inhibits glutamate release; its activation would counteract rather than propagate the glutamate burst. The downstream antidepressant cascade is initiated by ionotropic AMPA receptor activation, not mGluR2.
• Option C: Option C is incorrect because kainate receptors do not require glycine as a co-agonist and are not the primary receptor driving BDNF release and TrkB activation in the antidepressant cascade. The established mechanistic model specifically identifies AMPA receptor activation as the key step linking the glutamate burst to downstream neurotrophin signaling.
• Option D: Option D is incorrect because ketamine's dissociation from the NMDA channel pore is not rapid enough to permit significant re-activation within the timeframe of the glutamate burst at antidepressant concentrations. The antidepressant mechanism operates through AMPA receptor activation bypassing the blocked NMDA receptors, not through NMDA receptor recovery.
• Option E: Option E is incorrect because glycine receptors are inhibitory chloride channels activated by glycine, not by glutamate. They are not the receptor mediating the downstream antidepressant signaling cascade following ketamine-induced glutamate release.

ANSWER: D

Rationale:

The rapamycin experiment provides the key causal evidence for mTORC1's role in ketamine's antidepressant mechanism. When rapamycin was administered before ketamine treatment in animal models, it blocked both the ketamine-induced increase in synaptic proteins (including GluA1, PSD-95, and synapsin I) and the behavioral antidepressant effects measured in stress-based paradigms. This dual blockade — of both the structural (synaptogenic) and behavioral (antidepressant) outcomes — establishes that mTORC1-dependent protein synthesis is not merely correlated with the antidepressant effect but is causally necessary for it. Without mTORC1 activation and the resulting rapid translation of synaptic proteins, neither the new dendritic spine formation nor the behavioral antidepressant response occurs. This finding positions mTORC1 as an essential intermediary in the AMPA-BDNF-TrkB-mTORC1 cascade rather than an epiphenomenon of ketamine's NMDA receptor blockade.

• Option A: Option A is incorrect because rapamycin did not spare the behavioral antidepressant effect while only reducing synaptogenesis. Both outcomes were blocked, which is the finding that establishes causal necessity. A result in which only synaptogenesis was affected would suggest the two are dissociable and would not support mTORC1 as causally necessary for antidepressant action.
• Option B: Option B is incorrect because rapamycin does not potentiate ketamine's antidepressant effect. Rapamycin is an mTORC1 inhibitor, and mTORC1 activation is required for the downstream synaptogenesis; blocking it with rapamycin abolishes, not amplifies, ketamine's antidepressant effect.
• Option C: Option C is incorrect because rapamycin does not selectively block dissociation while sparing antidepressant action. Dissociation is a direct consequence of NMDA receptor blockade, not an mTORC1-dependent process. The mTORC1 pathway is downstream of NMDA blockade and governs synaptogenesis and antidepressant action; blocking it with rapamycin does not affect the acute dissociative pharmacodynamics.
• Option E: Option E is incorrect because the relevant experimental design that established causal necessity involved pre-treatment with rapamycin before ketamine, blocking both synaptogenesis and antidepressant effect from the outset. The established finding is that mTORC1 is required for the initiation of the full antidepressant cascade, not only for its maintenance.

ANSWER: A

Rationale:

(2R,6R)-hydroxynorketamine is a ketamine metabolite that has attracted substantial research interest because it produces antidepressant-like effects in animal models through a mechanism that does not require NMDA receptor blockade and does not produce the dissociative properties characteristic of ketamine itself. Studies by Zanos and colleagues demonstrated that (2R,6R)-HNK's antidepressant-like effects in rodent models were associated with potentiation of AMPA receptor signaling rather than NMDA antagonism, and that the metabolite lacked the stereotypy and ataxia typically produced by ketamine at comparable doses in those paradigms. This discovery raised the possibility that (2R,6R)-HNK could represent a lead compound for developing non-dissociative rapid-acting antidepressants. Whether (2R,6R)-HNK contributes meaningfully to the antidepressant effects of racemic IV ketamine in humans at the concentrations achieved after standard antidepressant dosing remains an active and unresolved area of investigation.

• Option B: Option B is incorrect because (2R,6R)-HNK is not the primary mediator of ketamine's dissociative effects. Dissociation is produced by ketamine's direct NMDA receptor blockade, not by this metabolite. (2R,6R)-HNK is notable precisely because it appears to produce antidepressant-like effects without the dissociation associated with the parent drug.
• Option C: Option C is incorrect because (2R,6R)-HNK is not an inactive metabolite. It has demonstrated pharmacological activity — specifically antidepressant-like effects in animal models — and has been the subject of active research as a potentially non-dissociative antidepressant mechanism.
• Option D: Option D is incorrect because (2R,6R)-HNK is not a more potent NMDA antagonist than ketamine; in fact, the research interest in this metabolite is specifically that it produces antidepressant effects WITHOUT significant NMDA receptor blockade. The three-to-seven-day antidepressant effect is attributed to the downstream cascade of synaptogenesis initiated by ketamine, not to norketamine or HNK plasma concentrations.
• Option E: Option E is incorrect because (2R,6R)-HNK does not act as a direct TrkB agonist at the extracellular BDNF binding domain. TrkB activation by (2R,6R)-HNK, if it occurs, is thought to be indirect through AMPA-dependent signaling. Direct TrkB binding at a transmembrane allosteric site has been attributed to ketamine itself and other antidepressants (Casarotto et al., 2021), not to this specific metabolite.

ANSWER: E

Rationale:

The pharmacokinetic basis for the higher nominal doses of intranasal esketamine compared with IV ketamine is its approximately 48% absolute bioavailability via the intranasal route. By definition, IV administration provides 100% bioavailability because the drug is delivered directly into the systemic circulation. Intranasal administration achieves only approximately 48% bioavailability because absorption through the nasal mucosa is incomplete and a portion of the administered drug is swallowed and undergoes hepatic first-pass metabolism rather than entering systemic circulation intact. To achieve systemic drug exposures sufficient for meaningful NMDA receptor occupancy and antidepressant effect, the nominal dose administered intranasally must be substantially higher than what would be needed intravenously. The 56 mg and 84 mg intranasal doses were selected through clinical pharmacokinetic and pharmacodynamic studies to produce the plasma concentrations and receptor occupancy associated with antidepressant efficacy despite this bioavailability limitation.

• Option B: Option B is incorrect because esketamine (the S-enantiomer) actually has approximately three to four times greater NMDA receptor affinity than arketamine (the R-enantiomer), making it the more potent NMDA antagonist. Lower receptor affinity is not the reason for the higher nominal dose; incomplete bioavailability via the intranasal route is.
• Option C: Option C is incorrect because intranasal administration does not bypass hepatic metabolism through direct lymphatic absorption. The nasal mucosa absorbs drug into the systemic venous circulation, not the lymphatic system. A portion of the administered dose is swallowed and undergoes conventional hepatic first-pass metabolism, contributing to the reduced bioavailability.
• Option D: Option D is incorrect because the primary route of esketamine metabolism is hepatic CYP3A4 and CYP2B6, not nasal mucosal monoamine oxidase. Monoamine oxidase is not a significant metabolic pathway for esketamine, and the description of MAO in the nasal mucosa as the mechanism of first-pass loss is pharmacokinetically inaccurate.
• Option A: Option A is incorrect because intranasal esketamine does not use a slow-release nasal mucosal coating. The reduced bioavailability is due to incomplete mucosal absorption and hepatic first-pass metabolism of the swallowed fraction, not a deliberate controlled-release formulation modification.

ANSWER: C

Rationale:

The antidepressant and anesthetic applications of ketamine are separated primarily by dose and the resulting degree of NMDA receptor occupancy across brain regions. The standard antidepressant dose of 0.5 mg/kg IV infused over 40 minutes is substantially below the anesthetic induction dose of 1 to 2 mg/kg IV. At the antidepressant dose, patients remain conscious but experience subanesthetic effects including dissociation, perceptual alterations, and mild increases in heart rate and blood pressure, which resolve within 60 to 90 minutes of infusion completion. At anesthetic induction doses of 1 to 2 mg/kg IV, the degree of NMDA receptor occupancy is sufficient to produce loss of consciousness, profound analgesia, and surgical immobility — the full dissociative anesthetic state. Both applications utilize the same mechanism of NMDA receptor blockade; the difference lies in the depth and extent of NMDA inhibition achieved at each dose range and the corresponding clinical state produced.

• Option A: Option A is incorrect because both the antidepressant and anesthetic effects of ketamine are primarily mediated through NMDA receptor blockade, not through receptor-specific separation. While opioid receptor interactions have been investigated as a contributing mechanism to ketamine's antidepressant effect, the primary mechanism at both dose ranges involves NMDA antagonism; the clinical difference is dose-dependent, not receptor-dependent.
• Option B: Option B is incorrect because there is a meaningful and clinically significant pharmacological difference between the two dose ranges. At 0.5 mg/kg, patients are conscious and experience subanesthetic dissociation; at 1 to 2 mg/kg, they lose consciousness and can undergo surgical procedures. Describing antidepressant dosing as merely incomplete anesthesia fails to account for the distinct downstream cascade (BDNF-TrkB-mTORC1 synaptogenesis) that occurs specifically at the lower dose range.
• Option D: Option D is incorrect because ketamine does not produce anatomically selective NMDA blockade based on limbic versus cortical circuits at antidepressant doses. Regional selectivity is determined by firing rates (use-dependence) and circuit-level activity patterns, not by a pharmacokinetically defined anatomical preference. The same drug reaches all brain regions; the preferential effect on tonically active interneurons is a functional, not anatomical, selectivity.
• Option E: Option E is incorrect because the antidepressant dose of 0.5 mg/kg and the anesthetic dose of 1 to 2 mg/kg IV do not produce identical plasma concentrations or receptor occupancy. The clinical differences directly reflect different plasma concentrations and different degrees of NMDA receptor occupancy, not differences in route of administration.

ANSWER: B

Rationale:

The SUSTAIN-1 trial was specifically designed to address the question of maintenance efficacy — whether continuing esketamine prevents relapse in patients who have already achieved stable remission. The trial used a randomized withdrawal design: patients first underwent an open-label induction phase on esketamine plus oral antidepressant, and those who achieved stable remission were then randomized in a double-blind fashion to either continue esketamine nasal spray plus oral antidepressant or switch to placebo nasal spray plus oral antidepressant. The primary endpoint was time to relapse. Patients who continued esketamine had significantly longer time to relapse than those switched to placebo, directly demonstrating that esketamine's benefit extends beyond the acute treatment phase and provides ongoing protection against relapse during maintenance therapy. This design — enrolling only patients who have already responded, then randomizing to continuation versus withdrawal — is the appropriate methodology for establishing maintenance efficacy and directly answers the clinical question of whether to continue treatment after remission.

• Option A: Option A is incorrect because TRANSFORM-2 was an acute efficacy trial that demonstrated superiority of esketamine over placebo nasal spray during the induction phase, with treatment differences emerging by day 2. It was not designed as a 12-month maintenance comparison, and the specific statistics described do not correspond to the TRANSFORM-2 findings.
• Option C: Option C is incorrect because the ASPIRE trials (ASPIRE-I and ASPIRE-II) were acute efficacy trials in patients with major depressive disorder with acute suicidal ideation or behavior (MDSI), not long-term maintenance trials. Their primary endpoint was MADRS reduction at four hours after the first administration, not relapse rates after transition to oral antidepressants.
• Option D: Option D is incorrect because SUSTAIN-1 is a published randomized controlled trial that provides controlled evidence for maintenance efficacy. The claim that no randomized trial has examined maintenance therapy is factually incorrect.
• Option E: Option E is incorrect because TRANSFORM-3 examined esketamine in older adults (aged 65 and older) during the acute treatment phase, not as a maintenance comparison after remission. It is not a trial demonstrating absence of maintenance benefit.

ANSWER: A

Rationale:

Treatment-resistant depression, as used in the esketamine FDA approval, is generally defined as inadequate response to at least two antidepressant treatments of adequate dose and duration in the current depressive episode. This definition requires both dose adequacy (reaching a therapeutically meaningful dose) and duration adequacy (maintaining that dose for a sufficient period, typically four to eight weeks, to allow for a full therapeutic trial). In this patient's history, the first trial was discontinued after only three weeks due to side effects before an adequate duration was completed, which raises the question of whether it constitutes a qualifying failed trial under the standard definition. The second trial at adequate dose and duration with no response clearly qualifies. A clinician applying the standard definition would need to assess whether the first early-discontinued trial should count toward the minimum threshold, as trials stopped early for tolerability reasons before adequate duration may not represent a true test of antidepressant efficacy. This nuance reflects the real-world complexity of applying the TRD definition to individual patients.

• Option B: Option B is incorrect because treatment-resistant depression does not require failure of four lifetime antidepressant trials. The standard definition used in the esketamine approval context is failure of two or more adequate trials, and these are typically assessed within the current depressive episode rather than accumulated across a lifetime of depressive episodes.
• Option C: Option C is incorrect because treatment-resistant depression is not defined by failure to achieve complete remission as measured by any specific scale. The standard definition requires inadequate response (which may include partial response) to adequate trials, and the adequacy of dose and duration are essential components of the definition.
• Option D: Option D is incorrect because the FDA-approved labeling for esketamine does specify the context of treatment-resistant depression as its indication, and the regulatory approval was based on trials enrolling patients with a defined TRD profile (failure of two or more adequate trials). The definition is not entirely unspecified or left to unconstrained clinical judgment.
• Option E: Option E is incorrect because treatment-resistant depression does not require trials from different pharmacological classes. Two trials from the same class (e.g., two different SSRIs) can both count as qualifying failed trials if each was conducted at adequate dose and duration. The definition focuses on the adequacy of the individual trials, not their pharmacological class diversity.

ANSWER: D

Rationale:

The FDA-approved labeling for esketamine (Spravato) and its REMS program explicitly require that esketamine be administered in conjunction with an oral antidepressant. This is not a practice guideline recommendation but a regulatory requirement embedded in the approved indication. The requirement for concurrent oral antidepressant use applies to both the TRD and MDSI indications. The clinical rationale is that esketamine's rapid-onset effects are intended to complement, not replace, a conventional antidepressant that provides sustained longer-term pharmacotherapy after esketamine's acute effect wanes. In the scenario described, the patient's refusal to take oral antidepressants creates a genuine clinical challenge that must be addressed — whether by identifying a tolerable oral agent (including those with different tolerability profiles such as bupropion, mirtazapine, or agomelatine where available), documenting the clinical decision-making, or reconsidering the treatment plan. Using esketamine outside its approved indication as monotherapy is not sanctioned by the REMS program.

• Option A: Option A is incorrect because there is no documented intolerance exception within the REMS program that permits esketamine monotherapy. The concurrent oral antidepressant requirement applies broadly, and the REMS program does not specify categories of patients for whom the co-administration requirement can be waived.
• Option B: Option B is incorrect because the requirement for concurrent oral antidepressant use applies to both the TRD and the MDSI indications. There is no indication-specific exception that permits esketamine monotherapy for patients with acute suicidal ideation while requiring concurrent oral antidepressant for TRD patients.
• Option C: Option C is incorrect because the FDA labeling does explicitly require concurrent oral antidepressant use. It is not silent on this requirement, and the REMS program requirements extend beyond the setting of administration and monitoring to include the co-administration mandate.
• Option E: Option E is incorrect because a REMS-certified psychiatrist does not have discretionary authority to prescribe esketamine as monotherapy based on informed consent alone. The concurrent oral antidepressant requirement is a regulatory condition of the approved labeling, not a default that can be waived by clinician discretion or patient consent.

ANSWER: E

Rationale:

The temporal dissociation between ketamine's acute dissociative effects and its antidepressant effect is one of the most pharmacologically instructive features of its mechanism. Dissociation is a direct pharmacodynamic consequence of NMDA receptor occupancy: it begins within minutes of infusion onset, correlates with plasma ketamine concentration, and resolves within 60 to 90 minutes as drug is cleared and NMDA receptor occupancy falls. The antidepressant effect, by contrast, is not directly produced by NMDA blockade itself but by the molecular cascade that NMDA blockade triggers: preferential blockade of GABAergic interneurons produces a glutamate burst, which activates AMPA receptors, stimulating BDNF release and TrkB signaling, driving mTORC1-dependent synthesis of new synaptic proteins and dendritic spine formation in prefrontal circuits. This structural remodeling reaches its functional peak at approximately 24 hours post-infusion — long after dissociation has fully resolved. The Clinician-Administered Dissociative States Scale (CADSS) quantifies dissociation intensity but does not predict antidepressant response, reflecting the mechanistic separation between these two effects.

• Option A: Option A is incorrect because dissociation severity does not predict antidepressant outcome. While both effects are initiated by NMDA receptor blockade, the magnitude of acute dissociation correlates with peak plasma drug concentration rather than with the downstream cascade of synaptogenesis that determines antidepressant efficacy. The two phenomena are mechanistically dissociated.
• Option C: Option C is incorrect because while opioid receptor involvement in ketamine's antidepressant mechanism has been investigated, it is not established that the antidepressant effect is entirely mediated by opioid receptor activation. The AMPA-BDNF-TrkB-mTORC1 cascade is the established mechanistic framework for ketamine's rapid antidepressant effect. Additionally, the dissociation of dissociation from antidepressant outcome is explained by the downstream cascade model, not by invoking a separate opioid mechanism.
• Option D: Option D is incorrect because ketamine's dissociative effects are not mediated by dopamine D2 receptors, and the antidepressant effects are not mediated through serotonin 2A receptor activation. Both effects originate from NMDA receptor blockade; the dissociation is a direct cortical NMDA effect, and the antidepressant effect reflects the downstream glutamatergic cascade.
• Option B: Option B is incorrect because while it correctly notes that dissociation resolves as plasma concentrations fall and that the antidepressant effect emerges from a downstream cascade, it fails to address the nurse's specific question about why dissociation severity does not predict antidepressant outcomes and does not provide the explicit temporal anchors — 60 to 90 minutes for dissociation resolution versus approximately 24 hours for antidepressant peak — that directly answer why the drug appears to work days after the acute episode resolves.

ANSWER: C

Rationale:

The standard blood pressure monitoring protocol for esketamine, as required under the REMS program, specifies measurement before each administration to establish a baseline, at 15-minute intervals during the administration and observation period to detect transient hypertension as it develops, and at the end of the monitoring period before the patient is cleared for discharge. This schedule reflects the pharmacodynamic profile of esketamine's cardiovascular effects: sympathomimetic blood pressure elevation through catecholamine reuptake inhibition begins during or shortly after administration, typically peaks during the infusion or early observation period, and returns toward baseline over 30 to 60 minutes. The 15-minute interval monitoring provides sufficient frequency to detect clinically significant blood pressure elevation and respond appropriately without requiring the continuous invasive monitoring used in intensive care settings. This same monitoring schedule is recommended for IV ketamine protocols even though IV ketamine lacks a formal REMS program, given the identical pharmacological basis for cardiovascular stimulation.

• Option A: Option A is incorrect because baseline-and-discharge-only monitoring is insufficient to detect the transient hypertensive response that typically peaks during the infusion or early observation period. Monitoring only at the endpoints would miss clinically significant intra-treatment blood pressure elevation that could require intervention.
• Option B: Option B is incorrect because continuous invasive arterial line monitoring is not required for esketamine or antidepressant-dose IV ketamine administration in outpatient or clinical office settings. This level of monitoring is appropriate for surgical anesthesia, not for the subanesthetic doses used in psychiatric treatment.
• Option D: Option D is incorrect because the blood pressure monitoring requirement under the REMS program applies to all patients receiving esketamine, not only those with pre-existing hypertension. Ketamine's sympathomimetic cardiovascular effects can produce clinically significant blood pressure elevation even in patients with normal baseline pressures.
• Option E: Option E is incorrect because a single measurement at 30 minutes does not conform to the REMS-specified monitoring protocol. The 15-minute interval schedule is required throughout the observation period, not limited to a single peak-concentration measurement, to ensure sustained monitoring as blood pressure effects evolve.

ANSWER: B

Rationale:

Ketamine-induced uropathy is a destructive bladder condition characterized by inflammatory infiltration and progressive fibrosis of the bladder wall, producing the syndrome of interstitial cystitis with markedly reduced bladder capacity, urinary frequency, urgency, and pain. Urothelial damage and submucosal fibrosis impair bladder compliance and capacity. In severe cases, the fibrotic bladder contracts to extremely small volumes, causing bilateral ureteric obstruction and hydronephrosis, with the potential for progressive renal damage. In the most severe cases, cystectomy with urinary diversion may be the only definitive treatment. This condition is associated with chronic high-dose recreational ketamine use. The mechanism is related to cumulative urothelial exposure to ketamine and its metabolites, though the precise pathological mechanism is not fully established. The condition is distinct from both hemorrhagic cystitis (which involves mucosal bleeding without the fibrotic component) and purely functional bladder disorders, and it does not respond to mesna prophylaxis because the pathological process differs fundamentally from acrolein-mediated bladder toxicity.

• Option A: Option A is incorrect because ketamine-induced uropathy is not a hemorrhagic cystitis and is not analogous to cyclophosphamide bladder toxicity. Cyclophosphamide produces hemorrhagic cystitis through the toxic metabolite acrolein, which alkylates urothelial cells and causes hemorrhage; mesna neutralizes acrolein and provides effective prophylaxis. Ketamine uropathy involves interstitial inflammation and fibrosis without the dominant hemorrhagic component and does not respond to mesna.
• Option C: Option C is incorrect because ketamine-induced uropathy is not a transient cholinergic overstimulation. Ketamine does not act as a muscarinic agonist. The bladder injury is a progressive, structurally destructive process involving fibrosis and urothelial damage that does not resolve within weeks of cessation in established cases, particularly when upper tract involvement has occurred.
• Option D: Option D is incorrect because ketamine-induced uropathy is not immune complex-mediated lupus cystitis. It is a direct toxic effect of ketamine and its metabolites on the urothelium and bladder wall, not a systemic autoimmune process. It does not respond to systemic corticosteroids as a definitive treatment.
• Option E: Option E is incorrect because the primary pathology of ketamine-induced uropathy is in the bladder wall (interstitial fibrosis), not in the kidney. While secondary upper tract involvement can occur as a consequence of bladder dysfunction, the initiating pathology is urothelial and submucosal fibrosis, not renal tubular acidosis, and the condition is not reversed by urinary alkalinization.

ANSWER: D

Rationale:

Arketamine, the R-enantiomer of ketamine, has attracted research interest as a potential non-dissociative antidepressant because it produces antidepressant-like effects in animal models of depression without the stereotypy, ataxia, and behavioral correlates of dissociation that esketamine produces at comparable doses. This apparent mechanistic separation is pharmacologically significant because arketamine has lower NMDA receptor affinity than esketamine — approximately three to four times less — suggesting its antidepressant-like effects may involve mechanisms other than, or in addition to, NMDA blockade. Proposed mechanisms include opioid receptor interactions and direct TrkB activation at the transmembrane allosteric site identified by Casarotto and colleagues, which would produce antidepressant-relevant neuroplasticity without requiring NMDA channel blockade. Arketamine is not currently FDA-approved for any psychiatric indication and has not completed the randomized controlled trials required for regulatory approval.

• Option A: Option A is incorrect because arketamine has not been approved by the FDA for any psychiatric indication. As of the current evidence base, only esketamine (S-enantiomer) has received FDA approval as the intranasal formulation Spravato. Arketamine remains an investigational compound.
• Option B: Option B is incorrect because arketamine has approximately three to four times lower NMDA receptor affinity than esketamine, not higher. Esketamine is the more potent NMDA antagonist and the more potent dissociative agent. The interest in arketamine is precisely that its lower NMDA affinity may correlate with reduced dissociative properties while retaining antidepressant activity through alternative mechanisms.
• Option C: Option C is incorrect because arketamine and esketamine do not have identical pharmacological profiles at the NMDA receptor. Esketamine has substantially greater NMDA receptor affinity. The research interest in arketamine is not primarily pharmacokinetic but pharmacodynamic — the possibility of dissociation-free antidepressant action through non-NMDA mechanisms.
• Option E: Option E is incorrect because ketamine-induced uropathy is associated with chronic high-dose recreational use of the racemic mixture, and its mechanism is related to cumulative urothelial exposure to ketamine metabolites, not specifically to the R-enantiomer. There is no established evidence that arketamine is selectively responsible for uropathy or that esketamine's single-enantiomer formulation confers lower uropathy risk than racemic ketamine at equivalent systemic exposures.

ANSWER: A

Rationale:

The ASPIRE-I and ASPIRE-II trials were the pivotal studies supporting esketamine's August 2020 FDA approval for the treatment of major depressive disorder with acute suicidal ideation or behavior (MDSI). These trials enrolled adult patients who were hospitalized with a current major depressive episode and active suicidal ideation or behavior, and they demonstrated statistically significant reductions in Montgomery-Asberg Depression Rating Scale (MADRS) scores at four hours after the first esketamine administration compared with placebo nasal spray, both in combination with standard-of-care treatment. The four-hour endpoint was chosen to capture the rapid-onset effect that distinguishes esketamine from conventional antidepressants and that is particularly relevant in the acute suicidal crisis context, where speed of response is clinically critical. This rapid separation from placebo at four hours, occurring before any oral antidepressant could have produced a meaningful effect, provided direct evidence for esketamine's ability to produce rapid antidepressant and anti-suicidal effects in this high-risk population and formed the clinical basis for the MDSI indication.

• Option B: Option B is incorrect because the ASPIRE trials enrolled patients with major depressive disorder with acute suicidal ideation or behavior, not bipolar depression. Esketamine does not have an FDA-approved indication for bipolar depression, and the ASPIRE program did not compare esketamine against lithium.
• Option C: Option C is incorrect because the ASPIRE trials were not negative studies. Both ASPIRE-I and ASPIRE-II demonstrated statistically significant reductions on the MADRS at four hours in the esketamine group compared with placebo. The MDSI approval was based on positive primary endpoints, not post-hoc suicidal ideation subscale analysis.
• Option D: Option D is incorrect because the ASPIRE trials did not use 12-week sustained remission as the primary endpoint. The primary efficacy endpoint was MADRS score change from baseline at four hours after the first administration, specifically chosen to assess rapid-onset effects relevant to the acute suicidal crisis setting.
• Option E: Option E is incorrect because hospitalization duration was not the primary endpoint of the ASPIRE trials. The primary endpoint was MADRS score change at four hours. While reducing hospitalization duration would have practical clinical value, the approval was based on the efficacy endpoint of rapid depression and suicidal ideation symptom reduction, not health-economic hospitalization outcomes.

ANSWER: E

Rationale:

The 2021 Cell paper by Casarotto and colleagues reported the discovery that antidepressant drugs, including ketamine, bind directly to TrkB (tropomyosin receptor kinase B) at an allosteric site within the transmembrane domain. This binding promotes TrkB dimerization and activation independently of BDNF, the receptor's endogenous ligand. This finding was pharmacologically significant for several reasons. First, it provided a unifying mechanism potentially common to structurally diverse antidepressants. Second, it established that ketamine's activation of TrkB — and the resulting downstream neuroplasticity signaling through PI3K/Akt/mTORC1 — does not depend entirely on BDNF availability in the synapse; the drug can directly transactivate the receptor. Third, it added a second, BDNF-independent pathway alongside the established AMPA-BDNF-TrkB cascade through which ketamine drives synaptic plasticity in prefrontal circuits. This transmembrane allosteric binding site on TrkB is now an active target for drug development aimed at producing antidepressant effects through direct TrkB activation without requiring NMDA receptor blockade or dissociation.

• Option A: Option A is incorrect because ketamine does not bind to the extracellular BDNF binding domain of TrkB. The binding site identified by Casarotto et al. is in the transmembrane domain, not the extracellular ligand-binding domain, and the mechanism is allosteric activation of dimerization rather than competitive partial agonism at the BDNF site.
• Option B: Option B is incorrect because ketamine does not block presynaptic BDNF reuptake transporters. The Casarotto finding describes direct drug-receptor binding at TrkB's transmembrane domain, not an indirect mechanism involving increased synaptic BDNF concentration through transporter blockade.
• Option C: Option C is incorrect because ketamine does not act as a direct intracellular protein kinase agonist. The binding site is in the transmembrane domain of TrkB, not in the intracellular kinase domain, and the mechanism is allosteric promotion of receptor dimerization, not direct kinase activation bypassing all extracellular and transmembrane structures.
• Option D: Option D is incorrect because while membrane lipid context and cholesterol can influence transmembrane receptor conformation, the Casarotto finding specifically identifies a direct drug binding site within the TrkB transmembrane domain rather than a cholesterol-mediated indirect membrane effect. The finding is about a defined allosteric binding interaction, not a lipid raft cholesterol-dependency mechanism.

ANSWER: C

Rationale:

The NMDA receptor is typically a tetramer consisting of two GluN1 subunits and two GluN2 subunits (with GluN3 subunits present in some receptor subtypes). The glutamate primary agonist site is located on the GluN2 subunit (specifically the GluN2A or GluN2B isoforms most relevant to synaptic plasticity in the adult brain), while the glycine or D-serine co-agonist site is located on the GluN1 subunit. For full channel activation, both the GluN2 glutamate site and the GluN1 co-agonist site must be occupied simultaneously, in addition to membrane depolarization relieving the Mg2+ block. This subunit-specific arrangement has direct pharmacological relevance: drugs targeting the glycine site on GluN1 (such as glycine site antagonists under development as alternative NMDA modulators) produce different receptor-level effects than drugs competing at the glutamate site on GluN2, and their interactions with channel-blocking agents like ketamine are pharmacologically distinct from competitive interactions at the same site. Ketamine itself binds within the channel pore, which is structurally separate from both the GluN1 co-agonist site and the GluN2 glutamate site.

• Option A: Option A is incorrect because glutamate and the glycine co-agonist do not bind to the same GluN2 subunit. They bind to different subunit types: glutamate to GluN2 and glycine or D-serine to GluN1. This subunit-specific separation of the two required ligand-binding events is a defining feature of the NMDA receptor's dual-agonist requirement.
• Option B: Option B is incorrect because it reverses the correct subunit assignments. Glutamate binds to GluN2 (not GluN1), and glycine or D-serine binds to GluN1 (not GluN2). This reversal is a common source of confusion and represents a pharmacologically meaningful error.
• Option D: Option D is incorrect because the glycine co-agonist site is not located within the ion channel pore. It is in the extracellular ligand-binding domain of the GluN1 subunit. Ketamine's binding site is within the channel pore (the open-channel blocker mechanism), which is structurally and pharmacologically distinct from the glycine co-agonist site on the extracellular domain.
• Option E: Option E is incorrect because the different subunit types of the NMDA receptor do not contain identical binding sites for both ligands. GluN1 and GluN2 subunits have structurally distinct ligand-binding domains, and the specific ligand recognized by each subunit type is determined by the structure of that subunit's extracellular binding domain, not merely the kinetics of channel opening.